Overview

A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight

Status:
Active, not recruiting
Trial end date:
2024-05-24
Target enrollment:
Participant gender:
Summary
This is a study of tirzepatide in participants with overweight and obesity. The main purpose is to learn more about how tirzepatide affects body weight. The study has two phases: A main phase and an extension phase. The main phase of the study will last 72 weeks (14 visits). Participants with prediabetes will continue in the extension for another 2 years.
Phase:
Phase 3
Details
Lead Sponsor:
Eli Lilly and Company
Treatments:
Tirzepatide